Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

NCT07498634 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

323

Enrollment

INDUSTRY

Sponsor class

Conditions

Phase III

Interventions

DRUG: XKH004
DRUG: Placebo

Sponsor

Zhejiang Kanova Biopharmaceutical Co., LTD